$AKCA News
Last published 1y ago
- 1y agoAKCAApproval of Tegsedi, Nda #211172 (REMS)FDA Approved DrugsApproval Date: 11/22/2024; Drug Name: Tegsedi, Nda #211172; Active Ingredients: INOTERSEN SODIUM; Company: Akcea Theraps; Submission Status: Approval; Submission Classification: REMS; Application Number: 211172
- 2y agoCTNMIONSNVSRNA+2Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of DirectorsBusiness WireContineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific
- 2y agoAKCAApproval of Tegsedi, Nda #211172 (Labeling)FDA Approved DrugsApproval Date: 01/12/2024; Drug Name: Tegsedi, Nda #211172; Active Ingredients: INOTERSEN SODIUM; Company: Akcea Theraps; Submission Status: Approval; Submission Classification: Labeling; Application Number: 211172
- 6y agoIONSAKCAIonis Pharmaceuticals completes acquisition of Akcea TherapeuticsPR NewswireIonis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the successful completion of its transaction to acquire 100% ownership of Akcea...
- 6y agoRSTAKCADCOMSBPHMoore Kuehn Encourages RST, AKCA, DCOM, and SBPH Investors to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
- 6y agoAKCAIONSWAYLIVRA▼® (volanesorsen), the First and Only Therapy for FCS, an Ultra-Rare and Life-Threatening Condition, to Be Available on the NHS in EnglandBusiness WireLONDON--(BUSINESS WIRE)--Akcea Therapeutics UK Ltd., a subsidiary of Akcea Therapeutics Inc. (NASDAQ: AKCA), announced today that the National Institute for Health and Care Excellence (NICE) has issued a positive Final Evaluation Document (FED) for volanesorsen for the treatment of Familial Chylomicronaemia Syndrome (FCS) for routine care on the National Health Service (NHS) in England. FCS is an ...
- 6y agoIONSAKCAIonis Pharmaceuticals to acquire remaining stake in Akcea TherapeuticsPR NewswireIonis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) today announced that they have entered into a...
- 6y agoAKCAIONSPositive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020PR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
- 6y agoAKCAIONSPositive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020PR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
- 6y agoAKCAIONSAkcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020PR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
- 6y agoAKCAIONSAkcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020PR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
- 6y agoAKCAIONSAkcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in GermanyPR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the German Association of...
- 6y agoAKCAIONSAkcea Reports Financial Results and Highlights for Second Quarter 2020PR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing...
- 6y agoAKCAIONSAkcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with PolyneuropathyPR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the Main Association of...
- 6y agoAKCAIONSAkcea Therapeutics to Hold Second Quarter 2020 Financial Results WebcastPR NewswireAkcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast...
- 6y agoAKCAIONSAkcea Appoints New Senior Vice President, Global Medical AffairsPR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Christophe Hotermans, M.D.,...
- 6y agoAKCAIONSAkcea Announces Appointment of New Chief Medical OfficerPR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that William Andrews, MD, FACP,...
- 6y agoAKCAIONSAkcea Appoints Tracy Palmer Berns as Chief Compliance OfficerPR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Tracy Palmer Berns has...
- 6y agoAKCAIONSAkcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare ConferencePR NewswireAkcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to ...
- 6y agoAKCAIONSAkcea Appoints New Senior Vice President, Business Development and Corporate StrategyPR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Kia Motesharei, Ph.D., has...
- 6y agoAKCAIONSAkcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathyPR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that AIFA, or The Italian...
- 6y agoAKCAIONSAkcea announces approval for reimbursement of TEGSEDI® (inotersen) in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathyPR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the Portuguese Medicine...
- 6y agoAKCAIONSAkcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Even Greater Stabilization in Patients Starting Earlier TreatmentGlobeNewswireResults from the ongoing, open-label extension (OLE) study of the pivotal NEURO-TTR trial published in the European Journal of Neurology show that patients treated with TEGSEDI® (inotersen)...
- 6y agoAKCAIONSAkcea Announces Appointment of New Chief Financial OfficerPR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Michael D. Price has joined...
- 6y agoAKCAIONSAkcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with PolyneuropathyPR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain...
- 6y agoAKCAApproval of Tegsedinda (REMS)FDA Approved DrugsApproval Date: 05/11/2020; Drug Name: Tegsedinda; Company: Akcea Theraps; Submission Status: Approval; Submission Classification: REMS; Application Number: 211172
- 6y agoAKCAIONSAkcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources OfficerPR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the ...
- 6y agoAKCAIONSAkcea Reports Financial Results and Highlights for First Quarter 2020PR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing...
- 6y agoAKCANationally Ranked Shareholder Rights Firm Labaton Sucharow Announces Proprietary Investigation of Akcea Therapeutics, Inc. (AKCA)Business WireNEW YORK--(BUSINESS WIRE)--Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf of shareholders of Akcea Therapeutics, Inc. (NASDAQ: AKCA).
- 6y agoAKCANationally Ranked Shareholder Rights Firm Labaton Sucharow Announces Proprietary Investigation of Akcea Therapeutics, Inc. (AKCA)Business WireNEW YORK--(BUSINESS WIRE)--Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf of shareholders of Akcea Therapeutics, Inc. (NASDAQ: AKCA).
- 6y agoAKCADr. Lisa Johnson-Pratt Joins Akcea Therapeutics as Senior Vice President, New Product Strategy; Joshua Patterson promoted to General Counsel, adding to the company’s leadership teamGlobeNewswireBOSTON, March 11, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Lisa Johnson-Pratt, M.D., has...
- 6y agoAKCAAkcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rare”GlobeNewswireBOSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the company’s support for Rare Disease...
- 6y agoAKCAAkcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results WebcastGlobeNewswireBOSTON, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on...
- 6y agoAKCAIONSAkcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRxGlobeNewswireFavorable safety and tolerability were observed Primary and multiple secondary endpoints were met with significant reduction in triglyceride levels, additional lipid parameters and ANGPTL3 ...
- 6y agoAKCAIONSAkcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L RxPR NewswireAkcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...
- 6y agoAKCAAkcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid CardiomyopathyGlobeNewswireBOSTON and CARLSBAD, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
- 6y agoAKCAIONSNew England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular DiseaseGlobeNewswirePatients treated with AKCEA-APO(a)-LRx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile Global Lp(a)HORIZON Phase 3 cardiovascular outcomes study...
- 6y agoAKCAAkcea Retains Rights to AKCEA-APOCIII-LRxGlobeNewswireBOSTON and CARLSBAD, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
- 6y agoAKCAAkcea Announces Appointment of New Chief Operating OfficerGlobeNewswireBOSTON, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that Alex Howarth has joined the company...
- 6y agoAKCAAkcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR AmyloidosisGlobeNewswireBOSTON and CARLSBAD, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
- 6y agoAKCAAkcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)GlobeNewswireBOSTON and CARSLBAD, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
- 7y agoAKCAAkcea Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireBOSTON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat...
- 7y agoAKCAAkcea Therapeutics, Inc. (AKCA) CEO Damien McDevitt on Q3 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 7y agoAKCAIONSAkcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness DayGlobeNewswireBOSTON, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today recognizes Familial Chylomicronemia...
- 7y agoSOLYAKCALVGOPFNX+1Biotech Brief: U.S. Medical Technology Market Projected To Exceed $200 Billion By 2023PR NewswireMedical device manufacturing remains a strong market, driven by technological developments, an aging population, and increases in chronic and...
- 7y agoAKCAIONSPFEAkcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)GlobeNewswireBOSTON and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Pfizer Inc. (NYSE:PFE),...
- 7y agoAKCAAkcea Therapeutics, Inc. (AKCA) CEO Paula Soteropoulos on Q1 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoAKCAAkcea Therapeutics' (AKCA) CEO Paula Soteropoulos on Q1 2018 Results - Earnings Call TranscriptEarnings Call Transcripts